Breaking Finance News

Zacks Investment Research downgraded Charles River Laboratories Intl. Inc (NYSE:CRL) to Hold in a report released today.

Yesterday Charles River Laboratories Intl. Inc (NYSE:CRL) traded -0.31% lower at $83.30. CRL’s 50-day average is $82.37 and its two hundred day average is $82.70. With the last stock price up 0.42% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 288,586 shares of the stock were exchanged, down from an avg. volume of 335,437

Zacks Investment Research has downgraded Charles River Laboratories Intl. Inc (NYSE:CRL) to Hold in a statement released on 10/7/2016.

Previously on 10/05/2016, Zacks Investment Research reported on Charles River Laboratories Intl. Inc (NYSE:CRL) bumped up the target price from $0.00 to $93.00 that suggested an upside of 0.12%.

Recent Performance Chart

Charles River Laboratories Intl. Inc (NYSE:CRL)

Charles River Laboratories Intl. Inc has a price-earnings ratio of 28.05 with a one year low of $63.68 and a one year high of $89.18 Charles River Laboratories Intl. Inc’s market capitalization is presently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 15 brokerages have released a report on Charles River Laboratories Intl. Inc. The 12-month price target is $85.47 with 6 equity analysts rating the company a strong buy, three firms rating the stock a buy, eight analysts rating the company a hold, 2 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Charles River Laboratories Intl. Inc (NYSE:CRL)

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *